A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

With Indivior’s stock price in freefall over the past year, one of the company’s top investors is taking leadership to task, ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially ...

Election Day is just about here, marking an end to the unpredictable ride that has been the 2024 presidential race following ...